drugset / Trial / NCT00338117
Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease
Phase 3
Completed
554 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Shire · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study was to determine the safety and effectiveness of a relatively high dose of galantamine, 32 mg /day in a three-times daily dosage, compared with placebo in treating patients with Alzheimer's disease.
Timeline
- Start
- 1995-08
- Primary completion
- —
- Completion
- 1997-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Galantamine | Small molecule | 40 mg | Oral |